Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma

University of Rostock

Status: Completed

Conditions: Allergic Asthma

Treatments: Drug: Salmeterol and Salmeterol / Fluticasone

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00736801

LO-1111

Details and patient eligibility

About

BDNF has been linked to the pathogenesis of airway hyperresponsiveness in asthma. In this trial, the impact of a treatment with salmeterol and salmeterol / fluticasone on BDNF concentrations will be assessed in patients with asthma. The investigators hypothesize that salmeterol impacts on BDNF concentrations in patients with asthma.

Enrollment: 35 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years, a physician's diagnosis of allergic asthma
• A documented sensitization to aero-allergens (pollen, animal hair, or house dust mite)
• A pre-bronchodilator forced expiratory volume in the first second (FEV1) > 80 % of the predicted value (% predicted), a provocative concentration of histamine causing a 20 % fall in FEV1 (PC20) of < 8 mg histamine / ml

Exclusion criteria

• No regular treatment (only short-acting inhalers on demand were allowed)
• No history of or evidence for any other chronic disease than asthma
• No history of smoking, absence of any signs or symptoms of an infection

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

35 participants in 1 patient group

A

Experimental group

Description:

Treatment with Salmeterol for 2 weeks, followed by a treatment with Salmeterol and Fluticasone for 2 weeks.

Treatment:

Drug: Salmeterol and Salmeterol / Fluticasone